RO200700700A8 - Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului - Google Patents

Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului Download PDF

Info

Publication number
RO200700700A8
RO200700700A8 ROA200700700A RO200700700A RO200700700A8 RO 200700700 A8 RO200700700 A8 RO 200700700A8 RO A200700700 A ROA200700700 A RO A200700700A RO 200700700 A RO200700700 A RO 200700700A RO 200700700 A8 RO200700700 A8 RO 200700700A8
Authority
RO
Romania
Prior art keywords
polymorph form
preparing
new crystalline
atorvastatin hemicalcium
hemicalcium salt
Prior art date
Application number
ROA200700700A
Other languages
English (en)
Romanian (ro)
Other versions
RO123642B1 (ro
Inventor
Jozsef Barkoczy
Nagy Peter Kotay
Gyula Simig
Judit Cselenyak
Zsuzsanna Szent-Kirallyi
Ferenc Bartha
Zoltan Katona
Donath Gyorgyi Vereczkeyne
Kalman Nagy
Norbert Nemeth
Gyorgy Ruzsics
Original Assignee
Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0500370A external-priority patent/HU0500370D0/hu
Priority claimed from HU0600120A external-priority patent/HUP0600120A3/hu
Application filed by Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag filed Critical Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag
Publication of RO123642B1 publication Critical patent/RO123642B1/ro
Publication of RO200700700A8 publication Critical patent/RO200700700A8/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ROA200700700A 2005-04-08 2006-04-07 Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului RO200700700A8 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0500370A HU0500370D0 (en) 2005-04-08 2005-04-08 New crystalline atorvastatin hemicalcium polimorph
HU0600120A HUP0600120A3 (en) 2006-02-14 2006-02-14 New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it
PCT/HU2006/000026 WO2006106372A1 (en) 2005-04-08 2006-04-07 New crystalline atorvastatin hemicalcium salt polymorph form

Publications (2)

Publication Number Publication Date
RO123642B1 RO123642B1 (ro) 2015-07-30
RO200700700A8 true RO200700700A8 (ro) 2015-07-30

Family

ID=89986585

Family Applications (1)

Application Number Title Priority Date Filing Date
ROA200700700A RO200700700A8 (ro) 2005-04-08 2006-04-07 Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului

Country Status (12)

Country Link
US (1) US20090215855A1 (cs)
EP (1) EP1868993B1 (cs)
JP (1) JP5523699B2 (cs)
BG (1) BG66035B1 (cs)
CZ (1) CZ2007772A3 (cs)
EA (1) EA014079B1 (cs)
IL (1) IL186499A (cs)
NO (1) NO20075721L (cs)
RO (1) RO200700700A8 (cs)
RU (1) RU2409563C2 (cs)
SK (1) SK288276B6 (cs)
WO (1) WO2006106372A1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080007561A (ko) 2005-12-13 2008-01-22 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
US20090240064A1 (en) * 2006-02-22 2009-09-24 Venkata Panakala Rao Gogulapati Crystalline form of atorvastatin hemi-calcium
US20120244220A1 (en) * 2009-12-25 2012-09-27 Sawai Pharmaceutical Co., Ltd. Atrovastatin-containing coated preparation
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
KR100431038B1 (ko) * 1995-07-17 2004-05-12 워너-램버트 캄파니 엘엘씨 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
KR100704213B1 (ko) * 2000-11-03 2007-04-10 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 ｖｉｉ형
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NZ527048A (en) * 2000-12-27 2004-12-24 Ciba Sc Holding Ag Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
KR100724515B1 (ko) * 2002-02-15 2007-06-04 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미칼슘의 신규한 결정형, 이의 제조 방법 및 아토르바스타틴 헤미칼슘 i형, viii형 및 ix형을 제조하는 신규한 방법
JP4422488B2 (ja) * 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム

Also Published As

Publication number Publication date
BG66035B1 (bg) 2010-11-30
US20090215855A1 (en) 2009-08-27
IL186499A (en) 2016-04-21
SK51252007A3 (sk) 2008-07-07
SK288276B6 (sk) 2015-06-02
EP1868993B1 (en) 2014-04-30
IL186499A0 (en) 2008-01-20
RO123642B1 (ro) 2015-07-30
NO20075721L (no) 2008-01-04
EA014079B1 (ru) 2010-08-30
EA200702191A1 (ru) 2008-04-28
EP1868993A1 (en) 2007-12-26
RU2409563C2 (ru) 2011-01-20
JP2008534669A (ja) 2008-08-28
BG109992A (bg) 2008-05-30
WO2006106372A1 (en) 2006-10-12
CZ2007772A3 (cs) 2008-02-27
RU2007140797A (ru) 2009-05-20
WO2006106372A8 (en) 2008-03-13
JP5523699B2 (ja) 2014-06-18
HK1117141A1 (en) 2009-01-09

Similar Documents

Publication Publication Date Title
YU56803A (sh) Pripremanje nekristalinskog atorvastatin-kalcijuma
UA78201C2 (en) Pharmaceutical formulation containing amorphous micronized atorvastatin calcium and method for preparation thereof
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
MX2007007845A (es) Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento.
TW200736258A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA04000889A (es) Formas cristalinas vi y vii de atorvastatina calcica.
EP2664620A3 (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline form and processes
NZ586720A (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
WO2005105738A3 (en) Salt forms of atorvastatin
IL266097B (en) " a mono-orotate acid addition salt of (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine”
RO200700700A8 (ro) Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului
CA2508871A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
MXPA05011497A (es) Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
SG141430A1 (en) Substituted pyrrole derivatives and their use as hmg-co inhibitors
WO2009007856A3 (en) Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
WO2010038948A3 (en) Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2005123670A3 (en) Crystalline form of a substituted pyrrolidine compound
NZ579339A (en) Atorvastatin strontium salt and pharmaceutical composition comprising the same
UA93202C2 (ru) Полиморфная форма кристаллической гемикальциевой соли аторвастатина
GR20050100466A (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
WO2009000286A8 (en) Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
WO2008078341A3 (en) Stable pharmaceutical formulations of atorvastatin magnesium salt
CA2469612A1 (en) Treatment of statin side effects using uridine derivatives
HK1119686A (en) Process for preparation of (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt